Tislelizumab (Development and Regulatory Status)
Tislelizumab was developed by BeiGene, a global biotechnology company. It has received approvals in various countries, including China, the United States, and the European Union, for multiple cancer types. Its development is part of a broader effort to provide innovative immunotherapy options for cancer patients worldwide.